ONCY (Oncolytics Biotech) OCF Margin %: 0.00% (As of Mar. 2026)


ONCY Oncolytics Biotech Inc ONCY
31 GF Score
Price $0.92
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech OCF Margin %?

Oncolytics Biotech ONCY -0.98% 31 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ONCY with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Oncolytics Biotech ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Oncolytics Biotech's Cash Flow from Operations for the three months ended in Mar. 2026 was $-7.29 Mil. Oncolytics Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Oncolytics Biotech's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Oncolytics Biotech's current OCF Yield % is -20.64%.

The historical rank and industry rank for Oncolytics Biotech's OCF Margin % or its related term are showing as below:


ONCY's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Oncolytics Biotech OCF Margin % Related Terms

Oncolytics Biotech OCF Margin % Historical Data

* Premium members only.

The historical data trend for Oncolytics Biotech's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech OCF Margin % Chart

Oncolytics Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oncolytics Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ONCY
31GF Score
Oncolytics Biotech Inc ONCY
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolytics Biotech OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Oncolytics Biotech's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-20.112/0
= %

Oncolytics Biotech's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.293/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Oncolytics Biotech (ONCY) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oncolytics Biotech and its competitors. According to the industry distribution chart, Oncolytics Biotech ranks #999999 out of 960 companies in the Biotechnology industry.
Is Oncolytics Biotech's OCF Margin % too high?
Oncolytics Biotech's current OCF Margin % is 0.00%. Based on the distribution chart, Oncolytics Biotech ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncolytics Biotech has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oncolytics Biotech's OCF Margin % compare to ALPS and KLRS?
According to the Biotechnology industry distribution chart, Oncolytics Biotech ranks #999999 out of 960 companies for OCF Margin %. This places Oncolytics Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Oncolytics Biotech and its competitors. Oncolytics Biotech's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolytics Biotech stock overvalued right now?
Oncolytics Biotech (ONCY) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Oncolytics Biotech's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Oncolytics Biotech (ONCY), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
31GF Score

Get the complete analysis for ONCY

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price